MY207001A - Salt and crystal form of compound having agonistic activity to s1p5 receptor - Google Patents
Salt and crystal form of compound having agonistic activity to s1p5 receptorInfo
- Publication number
- MY207001A MY207001A MYPI2022000691A MYPI2022000691A MY207001A MY 207001 A MY207001 A MY 207001A MY PI2022000691 A MYPI2022000691 A MY PI2022000691A MY PI2022000691 A MYPI2022000691 A MY PI2022000691A MY 207001 A MY207001 A MY 207001A
- Authority
- MY
- Malaysia
- Prior art keywords
- compound
- receptor
- salt
- crystal form
- agonistic activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889091P | 2019-08-20 | 2019-08-20 | |
| PCT/JP2020/031326 WO2021033729A1 (ja) | 2019-08-20 | 2020-08-19 | Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207001A true MY207001A (en) | 2025-01-23 |
Family
ID=74660224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2022000691A MY207001A (en) | 2019-08-20 | 2020-08-19 | Salt and crystal form of compound having agonistic activity to s1p5 receptor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12459890B2 (https=) |
| EP (1) | EP4019496B1 (https=) |
| JP (1) | JP7409383B2 (https=) |
| KR (1) | KR102930707B1 (https=) |
| CN (1) | CN114302873A (https=) |
| AU (1) | AU2020334489C1 (https=) |
| BR (1) | BR112022002632A2 (https=) |
| CA (1) | CA3150303A1 (https=) |
| ES (1) | ES2983098T3 (https=) |
| IL (1) | IL290432A (https=) |
| MX (1) | MX2022001820A (https=) |
| MY (1) | MY207001A (https=) |
| PH (1) | PH12022550319A1 (https=) |
| TW (1) | TWI859303B (https=) |
| WO (1) | WO2021033729A1 (https=) |
| ZA (1) | ZA202201784B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068382T2 (hu) * | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| US11919879B2 (en) | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| KR20250114133A (ko) * | 2022-12-16 | 2025-07-28 | 셀진 코포레이션 | S1p5의 조정제로서의 헤테로시클릭 화합물 |
| WO2025119254A1 (en) | 2023-12-06 | 2025-06-12 | Ono Pharmaceutical Co., Ltd. | Method for preparing dihydronaphthalene derivative |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234564A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| GB8725118D0 (en) * | 1987-10-27 | 1987-12-02 | Ciba Geigy Ag | Rifamycin derivatives |
| JP2005020882A (ja) | 2003-06-25 | 2005-01-20 | Matsushita Electric Works Ltd | モータアクチュエータ装置 |
| CN1874991A (zh) | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
| EP1661881B1 (en) | 2003-08-29 | 2014-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
| JP2006064757A (ja) | 2004-08-24 | 2006-03-09 | Systec Kyowa:Kk | ディスプレイ固定用スタンド |
| EP2592066B1 (en) | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
| AU2007212193A1 (en) | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| EP2086930A2 (en) * | 2006-06-12 | 2009-08-12 | Novartis AG | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| UA113507C2 (xx) | 2011-02-07 | 2017-02-10 | Модулятори s1p | |
| ES2852724T3 (es) | 2014-12-04 | 2021-09-14 | Ono Pharmaceutical Co | Derivados de dihidronaftaleno útiles en el tratamiento de enfermedades mediadas por S1P5 |
| ES2975689T3 (es) | 2016-01-29 | 2024-07-11 | Ono Pharmaceutical Co | Derivado de tetrahidronaftaleno |
| HUE068382T2 (hu) * | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| TW202114983A (zh) * | 2019-08-20 | 2021-04-16 | 日商小野藥品工業股份有限公司 | Ｓ１ｐ媒介疾病的預防及／或治療劑 |
-
2020
- 2020-08-19 CN CN202080056980.0A patent/CN114302873A/zh active Pending
- 2020-08-19 PH PH1/2022/550319A patent/PH12022550319A1/en unknown
- 2020-08-19 MY MYPI2022000691A patent/MY207001A/en unknown
- 2020-08-19 BR BR112022002632A patent/BR112022002632A2/pt unknown
- 2020-08-19 TW TW109128245A patent/TWI859303B/zh active
- 2020-08-19 AU AU2020334489A patent/AU2020334489C1/en active Active
- 2020-08-19 JP JP2021540972A patent/JP7409383B2/ja active Active
- 2020-08-19 EP EP20854718.2A patent/EP4019496B1/en active Active
- 2020-08-19 KR KR1020227004458A patent/KR102930707B1/ko active Active
- 2020-08-19 CA CA3150303A patent/CA3150303A1/en active Pending
- 2020-08-19 ES ES20854718T patent/ES2983098T3/es active Active
- 2020-08-19 WO PCT/JP2020/031326 patent/WO2021033729A1/ja not_active Ceased
- 2020-08-19 MX MX2022001820A patent/MX2022001820A/es unknown
- 2020-08-19 US US17/634,505 patent/US12459890B2/en active Active
-
2022
- 2022-02-08 IL IL290432A patent/IL290432A/en unknown
- 2022-02-10 ZA ZA2022/01784A patent/ZA202201784B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290432A (en) | 2022-04-01 |
| CA3150303A1 (en) | 2021-02-25 |
| KR102930707B1 (ko) | 2026-02-24 |
| US20220289675A1 (en) | 2022-09-15 |
| EP4019496B1 (en) | 2024-06-05 |
| JP7409383B2 (ja) | 2024-01-09 |
| MX2022001820A (es) | 2022-03-17 |
| PH12022550319A1 (en) | 2022-12-19 |
| TWI859303B (zh) | 2024-10-21 |
| ES2983098T3 (es) | 2024-10-22 |
| AU2020334489A1 (en) | 2022-03-03 |
| AU2020334489B2 (en) | 2025-10-30 |
| AU2020334489C1 (en) | 2026-03-26 |
| US12459890B2 (en) | 2025-11-04 |
| NZ785003A (en) | 2024-09-27 |
| BR112022002632A2 (pt) | 2022-05-03 |
| JPWO2021033729A1 (https=) | 2021-02-25 |
| KR20220050886A (ko) | 2022-04-25 |
| ZA202201784B (en) | 2024-02-28 |
| CN114302873A (zh) | 2022-04-08 |
| EP4019496A4 (en) | 2023-01-11 |
| EP4019496A1 (en) | 2022-06-29 |
| TW202114984A (zh) | 2021-04-16 |
| WO2021033729A1 (ja) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY207001A (en) | Salt and crystal form of compound having agonistic activity to s1p5 receptor | |
| PH12022551119A1 (en) | New methylquinazolinone derivatives | |
| NZ766978A (en) | Atr inhibitor and application thereof | |
| BR112017019420A2 (pt) | cartucho de bebida, método para montar um cartucho de bebida | |
| ZA202208051B (en) | Protein degradation agent compound preparation method and application | |
| EP4501323A3 (en) | Amino pyrimidine ssao inhibitors | |
| MY183536A (en) | Pharmaceutical compositions comprising azd9291 | |
| EA201691119A1 (ru) | Производные мочевины или их фармакологически приемлемые соли | |
| PH12016502539A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| EA201101138A1 (ru) | Соединение с конденсированным кольцом и его применение | |
| EP4692048A3 (en) | Methods of treating cdkl5 disorders with the compound ov329 | |
| IN2013DN02552A (https=) | ||
| AU2018274378A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
| NZ767352A (en) | Crystal form and salt form of pyridopyrazole compound and preparation method therefor | |
| MX2020008929A (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico. | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| PH12019501566B1 (en) | Amide compounds and use thereof | |
| MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. | |
| WO2012030957A3 (en) | Non-hygroscopic salts of 5-ht2c agonists | |
| MX379576B (es) | Derivados de azetidina | |
| MX2025001201A (es) | Sales y cristales novedosos | |
| ZA202007347B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| MX2022004215A (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4. | |
| MX370338B (es) | Composicion farmaceutica de derivado de aminodihidrotiazina condensado. | |
| EA201301136A2 (ru) | Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей |